STEK (Stemtech) Change In Payables And Accrued Expense : $2.36 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Stemtech Change In Payables And Accrued Expense?

Stemtech's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was $0.68 Mil. It means Stemtech's Accounts Payable & Accrued Expense increased by $0.68 Mil from Jun. 2024 to Sep. 2024 .

Stemtech's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $0.96 Mil. It means Stemtech's Accounts Payable & Accrued Expense increased by $0.96 Mil from Dec. 2022 to Dec. 2023 .

Stemtech Change In Payables And Accrued Expense Historical Data

The historical data trend for Stemtech's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stemtech Change In Payables And Accrued Expense Chart

Stemtech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

0.36

1.22

-0.68

0.96

Stemtech Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial												0.32	0.13	1.10	0.46	0.68

Stemtech Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.36 Mil.

Stemtech Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Stemtech's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Stemtech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Stemtech Corp (OTCPK:STEK) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

4851 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103

Website

https://www.stemtech.com

Stemtech Corp is a nutraceutical company. Its products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where perform their daily function of renewal for optimal health. It markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze. Geographically, it derives a majority of its revenue from the Americas.

Executives

Charles Stuart Arnold	director	520 BRICKELL KEY DR #1607, MIAMI FL 33131
Mindshare Holdings, Inc.	10 percent owner	419 BOSTWICK LANE, GAITHERSBURG MD 20878
Darryl V Green	director	300 SIXTH AVENUE, PITTSBURGH PA 15222
John William Meyer	director	10370 USA TODAY WAY, MIRAMAR FL 33025
Benjamin Nathaniel Kaplan	director	13005 CORONOADO LANE, NORTH MIAMI FL 33181